Layoffs
Filter News
Found 153 articles
-
Boston Scientific's restructuring will take place over a three-year period. The company expects it overall employee base to remain relatively unchanged when it is complete, although some losses are expected.
-
Theranos fit in with the opaque culture of Silicon Valley, which allowed it to thrive and amass a fortune without delivering anything, book argues.
-
In the wake of a Complete Response Letter issued by the FDA, Trevana, Inc. is slashing one-third of its workforce. On Wednesday, Merrimack Pharmaceuticals also announced it was terminating 60 percent of its staff as the company narrows its research and development focus.
-
Shares of South San Francisco-based Achaogen, Inc. fell more than 12 percent in Monday trading after the company signaled that it began a review of strategic alternatives that could include a sale of the company.
-
According to Jay Bradner, president of the Novartis Institutes for Biomedical Research, the company is cutting its drug programs from 430 to 340. One of the big areas the company is abandoning is infectious diseases. The decision is a result of a strategic review by Vasant (Vas) Narasimhan, the c...
-
Citing structural simplification, Pfizer announced it plans to cut its global staffing by about 2 percent. It expects to do so primarily through voluntary layoffs and early retirement through the end of this year and early in 2019.
-
Cesca Therapeutics Announces Cost Reduction Measures Aimed at Achieving Cash Flow Positive Position in 2019
10/16/2018
Cesca Therapeutics (NASDAQ: KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, announced today the departure of Vivian Liu, Chief Operating Officer, and Joseph Balagot, Senior Vice President of Corporate Development, and one other member of the managerial team.
-
German company Bayer AG is laying off 227 staffers at its manufacturing plant in Berkeley, California. Most of the cuts took place on October 3.
-
Despite winning regulatory approval for a copycat version of Copaxone earlier this year, Cambridge, Mass.-based Momenta Pharmaceuticals has completed a strategic review that includes slashing its staff by 50 percent as the company focuses its resources on two biosimilar candidates in its pipeline.
-
Earlier this month, Novo Nordisk announced it was laying off 400 staffers in Denmark and China. Today, Reuters reports that the Danish company plans to lay off about 250 people in the United States.
-
Swiss pharmaceutical giant Novartis plans to slash approximately 2,200 jobs in Switzerland over the next four years.
-
Novo Nordisk is laying off 400 staffers so it can shift funds toward biological and technological innovation.
-
Realm Therapeutics Slashes Staff and Explores Potential Sale as the Company Conducts a Strategic ...
9/17/2018
Following a trial failure with its atopic dermatitis treatment, Malvern, Penn.-based Realm Therapeutics has opted to discontinue all of its drug development programs and is considering a potential sale of the company. -
Takeda Pharmaceuticals will shutter its Deerfield, Ill. U.S. headquarters and move the operations to Boston as the company consolidates its operations following the $62 billion acquisition of Shire.
-
Job hunting can be a challenging time for people. Finding open positions that fit your skill set and then competing with other highly-qualified people can be bruising, especially if you’re already a bit damaged from a recent layoff.
-
A patient advocacy organization is putting its weight behind an effort to urge the U.S. Food and Drug Administration to reconsider its recent decision to reject a treatment for the rare lipid disorder familial chylomicronemia syndrome (FCS). That rejection lead to a round of layoffs at Akcea.
-
As part of an earlier announced restructuring program, UK-based GlaxoSmithKline is laying off 650 staffers in the U.S. GlaxoSmithKline employees approximately 15,000 people in the U.S.
-
Genentech is slashing 223 jobs at its South San Francisco headquarters, according to a Worker Adjustment and Retraining Notification posted on a California state government website. The layoffs will go into effect on Aug. 31, according to the WARN posting.
-
Updated: Boston Scientific Continues M&A Spree with $160 Million Deal for Veniti; Lays Off 85 in ...
8/8/2018
Two days after Boston Scientific laid off 85 employees at a Burlington, Mass. manufacturing site, the company forked over up to $160 million to acquire California stent maker Veniti, Inc. The deal marks the third acquisition for Boston Scientific in two months. -
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter—basically a rejection—to Austin, Texas-based Pain Therapeutics for Remoxy ER for pain.